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one half of those in the intravenous group.3 Four trials
have compared different intravenous antibiotics given
for 7-14 days, with 3-4 days of intravenous and 4-14
days of oral therapy.2 No differences in recurrence of
urinary tract infection and renal parenchymal abnor-
mality were found. So what do we conclude? Oral anti-
biotics, carefully chosen to cover local uropathogens,
are as safe and effective as intravenous antibiotics in
children with a clinical diagnosis of acute pyelonephri-
tis. This is not surprising given the combination of high
bioavailability and renal excretion of orally adminis-
tered antibiotics. Intravenous treatment should be pre-
served for children who are seriously ill, or who fail
oral treatment because of persistent vomiting. There is
no evidence to support the practice of giving a single
dose of parenteral antibiotics in addition to a standard
course of orally administered antibiotics.5
Which antibiotic should be given? The five trials
comparing different antibiotics are largely uninforma-
tive for routine clinical care because the antibiotics
evaluated have limited availability and are not routinely
used.2 Choice of first line oral antibiotics will vary with
local antibiotic resistance patterns, but trimethoprim
alone or in combination with sulphamethoxazole,
cephalexin or amoxicillin-clavulanic acid are standard
first line agents. Given that E coli is the causative organ-
ism in 90% of cases and that -lactamase production is
present in at least 50%, amoxicillin alone should not
be used.
If intravenous antibiotics are required, aminoglyco-
sides or third generation cephalosporins are often given.
Aminoglycosides are favoured because of their pharma-
cokinetic properties, efficacy, widespread availability, and
low cost. Three trials, which compared a single daily
dose with three times daily doses of aminoglycosides,
have shown no differences in persisting bacteriuria, time
to resolution of fever, recurrence of urinary tract
infections, hearing impairment, or renal dysfunction.6–8
These results are similar to data from studies in adults,
where toxicity tends to favour single dose treatment.9
Given the equivalence of the dosing regimens, the ease
of administration, and reduced nursing time, once daily
dosing seems preferable in general.
How long should antibiotics be given for? In
children with urinary tract infection other than pyelone-
phritis, there is evidence that short course treatment (3-4
days) is as effective as standard course (7-10 days) treat-
ment.10 However, none of the three trials examining
duration of treatment in children with pyelonephritis
have compared these clinically relevant alternatives.2
Since children with acute pyelonephritis typically take
3-4 days to recover clinically, it seems prudent to
continue antibiotic treatment for 7-10 days until further
trials examining treatment duration are performed.
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Health claims for functional foods
Regulations vary between countries and often permit vague claims
Functional foods are foods that claim to improvewellbeing or health.1 The health claim may beimplicit (“rich in vitamin C”), or vague
(“strengthens the body’s defence system”), but invari-
ably the product is presented with the suggestion of a
benefit. Sales of such products are huge and growing.
What ingredients do such foods contain—and who
safeguards the truth of claims?
Many functional foods contain added vitamins,
minerals, and other essential nutrients. Some of these
added nutrients indeed promote health: folic acid
reduces the risk of neural tube defects, table salt with
potassium reduces blood pressure, and polyunsatu-
rated fatty acids reduce the risk of heart disease. But
other claims are more dubious—for example, that zinc
lozenges protect against colds or that drinks rich in
vitamin C protect against cardiovascular disease.
Functional foods may also contain non-nutritive
ingredients. Examples of effective non-nutritive ingredi-
ents are sugar alcohols in chewing gum, which reduce
risk of dental caries; plant stanols and sterols, which
lower low density lipoprotein cholesterol (although
effects on heart disease remain to be shown); and pro-
biotic bacteria, which may diminish rotavirus diarrhoea
in infants. But other effects of probiotics are insuffi-
ciently substantiated, as are effects of phytoestrogens
against breast cancer,2 of oligosaccharides for “gut
health,” of flavonoids against heart disease, and of conju-
gated linoleic acid for weight loss. Herbs such as Kava,
St John’s wort, and echinacea can also be considered
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non-nutritive ingredients. They are sold as supplements
and added to foods, but their efficacy is controversial
and concern remains over potential harm.3
Functional foods are marketed directly to consum-
ers, who are unable to assess the implied health claims.
Consumers thus must rely on their governments to
make sure that they are not misled. Unfortunately, cur-
rent government regulations leave room for mislead-
ing claims. Deception is promoted by the fact that
legislation of health claims for foods is layered: there
are soft claims, which require soft evidence, and hard
claims, which require harder evidence. For example, a
draft regulation of the Codex Commission of the
United Nations, which sets international food stand-
ards, recognises claims about nutrient content (“rich
in calcium”) and disease reduction (“prevents osteo-
porosis”), as well as various intermediate categories.
Manufacturers have therefore made the formulation of
soft claims into a fine art, creating claims that imply
health effects without actually naming a disease.
Regulations differ between countries. Japan was the
first country to recognise functional foods as a separate
category when in 1991 it introduced the FOSHU
(Foods for Specific Health Use) system to evaluate
health claims. This system has valuable aspects: it regu-
lates both safety and health, and it demands that the
food be analysed for the amount of effective
component.4 But it is voluntary, and even though the
evidence required has been reduced in recent years
and is minimal by pharmaceutical standards, most
manufacturers opt for softer categories of claims,
which require little evidence. An example is the
unproved but lawful statement that extra vitamins help
to maintain healthy skin and mucosa. Watering down
of regulations has also occurred in the United States,
which once had a solid system for disease reduction
claims for foods, which were allowed only if there was
“significant scientific agreement” that the claim was
valid.5 However, the Food and Drug Administration’s
oversight over health claims has eroded, and the
United States now allows “qualified health claims” for
which there is hardly any evidence, as long as a
disclaimer is included. In the European Union the
safety of novel foods is thoroughly regulated but health
claims are not—EU legislation for nutrition claims is
complex, fragmented, and poorly enforced. Paradoxi-
cally, current EU regulations prohibit claims that a
food ingredient prevents a disease even when the claim
is true—for example, that folic acid prevents neural
tube defects. Finally, Canada, Australia, and New
Zealand have introduced new systems to regulate
health claims, but experience with these is still limited.
The lack of proper regulatory oversight has led to
some functional foods that are no more than quackery,
while at the same time other functional foods do pro-
mote health and prevent disease. The potential for
effective functional foods is certainly there. Foods and
food components could prevent or ameliorate many
diseases,6 7 but not enough research is being done to
identify effective ingredients and substantiate their effi-
cacy and safety. Whether such research will be done
depends to a large extent on proper regulation. Major
food companies are eager to expand into health
promoting foods, but there is no incentive to underpin
such health effects with solid research when products
can be successfully marketed on the basis of vague
allusions alone. But there is hope. After more than 20
years of deliberations the European Commission
recently agreed on new regulations that would prohibit
vague claims and that would allow hard claims of
disease reduction for foods if the evidence is solid.8 The
commission even wants to grant companies seven
years of exclusivity for truly novel claims backed up by
solid data. If the European Parliament accepts these
proposals it would be a step in the right direction.
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Suspension of doctors
The process is badly handled at present, and new guidance is welcome
For any employee to be excluded from work is adevastating blow, whatever the circumstances. Inthe case of doctors the safety of patients may be
a justifiable reason, but the process that leads to that
decision is not straightforward and in many cases the
individuals concerned, their colleagues, and the
patients feel confused and uninformed.
A recent report from the National Audit Office has
confirmed what many suspected and some have
suffered at first hand—that the process of suspension
has to date been haphazard and badly handled in
many NHS organisations.1 Following this report comes
new guidance from the Department of Health,
contained in a direction to NHS trusts that has to be
applied to all suspensions.
The report from the National Audit Office is forth-
right about the expensive and damaging consequences
that result when suspensions are performed badly. The
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